FDA Advocacy

Learn about our work to bring the voice of people concerned about women’s health to decision-makers who create and implement health policies.

Featured Posts

Sorry, we couldn't find any content.

Browse our FDA ADVOCACY work:

  • Filter by Category:

  • Sort by:

Results for:

Natural Cycles is a high-tech version of the classic rhythm method (also called natural family planning or the fertility awareness method) in which users track their ovulation cycles in order to avoid pregnancy. Updated: Oct 27, 2018

Natural Cycles is a high-tech version of the classic rhythm method (also called natural family planning or the fertility awareness method) in which users track their ovulation cycles in order to avoid pregnancy. But an app does not = birth...

FOR IMMEDIATE RELEASE Contact: Cynthia Pearson, cpearson@nwhn.org or (202) 682-2640, x222

In our current political climate, each day brings new attacks on reproductive health. Between the Trump-Pence administration’s attacks on access to birth control and Congress’s continual efforts to curtail abortion care, we are in an uphill battle when it comes...

Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women. Updated: Jul 30, 2019

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-2640

The first year of the Trump presidency has brought an almost endless slew of scandals, resignations, and exposés. It often feels like we’re watching reality TV, and sometimes it seems like we no longer even expect qualified government officials to...

Given the divisiveness of our current political climate, it sometimes seems like Americans simply cannot agree on anything. Reducing costs of prescription drug prices may be the exception!

As FDA Commissioner, will Scott Gottlieb be the right choice in defending women's health? (Spoiler alert: probably not!)

FDA Meeting – Risk Benefit Assessment

By: Caila Brander , Testimony

Testimony Delivered at the FDA Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making